Welcome to our dedicated page for CBRA SEC filings (Ticker: CBRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Caring Brands, Inc. filings document the company's public offering registration, material agreements and capital-structure changes as a Nevada operating company. Registration statements and current reports describe common stock, underwriting arrangements, Series A Convertible Preferred Stock, common-stock warrants, conversion and exercise limits, and share-redemption arrangements.
The filing record also covers intellectual-property events related to the Hair Enzyme Booster product and formal Nasdaq listing-compliance matters tied to stockholders' equity standards. These disclosures frame the company's securities, governance, financing activity, product-related patent portfolio and exchange-status reporting.
Caring Brands, Inc. filed an initial ownership report showing that a reporting person who is both a director and a 10% owner holds a significant stake in the company. As of the event date of 10/30/2025, this individual beneficially owns 2,000,000 shares of common stock, held directly. No derivative securities such as options or warrants are reported in the filing. This Form 3 establishes the insider’s starting ownership position now that they are subject to insider reporting rules.
Caring Brands, Inc. filed its Q3 2025 10‑Q reporting minimal revenue and continued losses. For the three months ended September 30, 2025, net sales were $740 and net loss was $1,018,768. Selling, general and administrative expenses were $999,923, driven by legal, consulting and investor relations costs. For the nine months, revenue totaled $3,795 and net loss was $2,218,121.
Cash was $16,123 as of September 30, 2025, with total current liabilities of $570,210. The company drew $120,000 on a convertible note carrying 10% interest and issued 200,000 warrants at $4.00; related‑party loans totaled $129,405, including $75,000 from executives and $54,405 paid by an affiliate. It recorded $225,000 year‑to‑date amortization on a $3,000,000 NovoDX license (net carrying amount $2,625,000). Management disclosed a going concern uncertainty and a material weakness in internal controls. Shares outstanding were 13,736,925 as of September 30, 2025.
Caring Brands, Inc. filed an amended S-1 registration indicating 13,736,925 shares of common stock issued and outstanding as of October 9, 2025. The filing shows an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, implying a public offering structure that yields $3,680,000 before expenses on the stated tranche. The company reports historical operating losses and working capital movement, with reported changes in cash of $(395,105) and $305,284 for the presented periods.
The company holds an exclusive license and subsequently acquired assets for the product Photocil (license in July 2021; asset acquisition in June 2022), launched commercially in India in September 2022 and initially entered the U.S. via Amazon in Q4 2022 before removal from the U.S. market in 2023 due to insufficient sales. Management plans to apply for a National Drug Code (NDC) number prior to any U.S. relaunch. The filing discloses clinical trial publications and a reported p-value p < 0.03 cited as statistically significant. A new Chief Financial Officer, Tyler Moore, was appointed effective September 4, 2025.
Caring Brands, Inc. (CBRA) filed an amendment to its S-1 registration describing a planned offering and company history. As of September 5, 2025 the company had 13,736,925 shares of common stock issued and outstanding. The prospectus shows a public offering price implied at $4.00 per share with an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, totaling proceeds of $3,680,000 (with related underwriting fees of $320,000). The filing discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030).
The company acquired Photocil assets in June 2022 after obtaining an exclusive license in July 2021, launched the product in India in September 2022 (OTC) and entered the U.S. market in Q4 2022 but removed it from the U.S. market in early/mid 2023 because of insufficient sales. The filing states plans to apply for an NDC for FDA registration prior to a U.S. relaunch. Clinical trial publications and a reported p-value 0.03 are referenced.
Caring Brands, Inc. (CBRA) filed an amendment to its S-1 registration describing a planned offering and company history. As of September 5, 2025 the company had 13,736,925 shares of common stock issued and outstanding. The prospectus shows a public offering price implied at $4.00 per share with an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, totaling proceeds of $3,680,000 (with related underwriting fees of $320,000). The filing discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030).
The company acquired Photocil assets in June 2022 after obtaining an exclusive license in July 2021, launched the product in India in September 2022 (OTC) and entered the U.S. market in Q4 2022 but removed it from the U.S. market in early/mid 2023 because of insufficient sales. The filing states plans to apply for an NDC for FDA registration prior to a U.S. relaunch. Clinical trial publications and a reported p-value 0.03 are referenced.
Caring Brands, Inc. (CBRA) filed an amendment to its S-1 registration describing a planned offering and company history. As of September 5, 2025 the company had 13,736,925 shares of common stock issued and outstanding. The prospectus shows a public offering price implied at $4.00 per share with an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, totaling proceeds of $3,680,000 (with related underwriting fees of $320,000). The filing discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030).
The company acquired Photocil assets in June 2022 after obtaining an exclusive license in July 2021, launched the product in India in September 2022 (OTC) and entered the U.S. market in Q4 2022 but removed it from the U.S. market in early/mid 2023 because of insufficient sales. The filing states plans to apply for an NDC for FDA registration prior to a U.S. relaunch. Clinical trial publications and a reported p-value 0.03 are referenced.
Caring Brands, Inc. (CBRA) amended its S-1 registration to detail an offering and provide updated corporate and financial information. The company reports 13,736,925 shares of common stock outstanding as of September 5, 2025, and discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030). The prospectus shows an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, with aggregate proceeds before expenses shown as $3,680,000. Financial excerpts show operating losses, limited revenue and cash activity, including an increase (decrease) in cash of $(395,105) and $305,284 in comparative periods. The filing describes the Photocil asset acquisition and exclusive license history, past U.S. commercialization and removal from the U.S. market due to insufficient sales, and plans to seek an NDC for a U.S. relaunch. Corporate governance, board composition, committees, related party transaction disclosure and disclosure of potential licensing discussions in Europe and South America are included.
Caring Brands, Inc. (CBRA) amended its S-1 registration to detail an offering and provide updated corporate and financial information. The company reports 13,736,925 shares of common stock outstanding as of September 5, 2025, and discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030). The prospectus shows an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, with aggregate proceeds before expenses shown as $3,680,000. Financial excerpts show operating losses, limited revenue and cash activity, including an increase (decrease) in cash of $(395,105) and $305,284 in comparative periods. The filing describes the Photocil asset acquisition and exclusive license history, past U.S. commercialization and removal from the U.S. market due to insufficient sales, and plans to seek an NDC for a U.S. relaunch. Corporate governance, board composition, committees, related party transaction disclosure and disclosure of potential licensing discussions in Europe and South America are included.
Caring Brands, Inc. (CBRA) amended its S-1 registration to detail an offering and provide updated corporate and financial information. The company reports 13,736,925 shares of common stock outstanding as of September 5, 2025, and discloses outstanding warrants to purchase up to 2,110,000 shares at $3.00 (expiring May 1, 2027) and 200,000 warrants at $4.00 (expiring August 6, 2030). The prospectus shows an underwriting discount of $0.32 per share and proceeds to the company of $3.68 per share, with aggregate proceeds before expenses shown as $3,680,000. Financial excerpts show operating losses, limited revenue and cash activity, including an increase (decrease) in cash of $(395,105) and $305,284 in comparative periods. The filing describes the Photocil asset acquisition and exclusive license history, past U.S. commercialization and removal from the U.S. market due to insufficient sales, and plans to seek an NDC for a U.S. relaunch. Corporate governance, board composition, committees, related party transaction disclosure and disclosure of potential licensing discussions in Europe and South America are included.